Dendreon Photos

Morris Plains Campus
Dendreon

+ Add Photo

Dendreon Reviews

2.7
Rating Trends
Recommend to a friend
Approve of CEO
Dendreon President & CEO John H. Johnson
John H. Johnson
37 Ratings
  • How it was

    • Work/Life Balance
    • Culture & Values
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Former Employee - Anonymous Employee
    Former Employee - Anonymous Employee

    I worked at Dendreon (More than 8 years)

    Doesn't Recommend
    Negative Outlook
    Disapproves of CEO
    Doesn't Recommend
    Negative Outlook
    Disapproves of CEO

    Pros

    Great coworkers committed to excellence

    Cons

    Too many layoffs within the past few years


Dendreon Interviews

Interview Experience

Interview Experience

54%
28%
17%

Getting an Interview

Getting an Interview

51%
16%
16%

Interview Difficulty

2.8
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Unable to Divulge - Currently Employed Interview

    Anonymous Interview Candidate in Union City, GA
    Accepted Offer
    Positive Experience
    Average Interview

    Application

    I applied through an employee referral. The process took 2+ weeksinterviewed at Dendreon (Union City, GA).

    Interview

    The interview process was wonderful. I met with two individuals in a sit-down meeting. It was moderately casual, yet professional. Both managers made me feel at ease, and asked insightful questions while giving me more information about the company and the position.

    Interview Questions

Dendreon Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.dendreon.com
Headquarters Seattle, WA
Size 500 to 999 Employees
Founded 1992
Type Company - Public (DNDN)
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

Dendreon wants to boost your immunity from the start. It is developing therapeutic vaccines that help the body's immune system fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its sole commercial product, Provenge, is a therapeutic vaccine that targets prostate cancer. Provenge gained the status of being the first therapeutic cancer vaccine to receive FDA approval in 2010. Dendreon is also working on a therapeutic vaccine to treat breast, bladder, and ovarian cancers, and it has research programs investigating... More

Work at Dendreon? Share Your Experiences

Dendreon

 
Click to Rate
or